US-based anatomic pathology lab GoPath Diagnostics has unveiled DiabetesNow, a genetic test panel aimed at enhancing diabetes diagnosis and management.
The tool merges testing for 16 genes linked to monogenic diabetes forms, such as MODY and neonatal types, with polygenic risk scores for type 1 and type 2 diabetes across various ancestries.
The test panel also includes GenProb-T1D, estimating type 1 diabetes likelihood through genetic and clinical data.
DiabetesNow is designed to identify key SNPs associated with both type 1 and type 2 diabetes, clarifying uncertain cases by pinpointing inherited gene variants.
The capability supports early detection in at-risk family members and distinguishes MODY from type 1 and type 2 diabetes, crucial for guiding treatment and medication decisions.
The test panel benefits early-onset or atypical cases, including patients with mild or non-progressive hyperglycaemia or atypical diabetes symptoms.
The selection of the 16 genes is based on recommendations from the Monogenic Diabetes Expert Panel and current clinical literature.
GoPath Diagnostics leverages its internal database of previously tested patients to ensure robust variant interpretation and clinically actionable reporting.
Each DiabetesNow report includes monogenic variant analysis, PRS percentile rank by ancestry, and a GenProb-T1D score, providing comprehensive insights in a single report.
The development of DiabetesNow incorporates the latest advancements in diabetes genetics, drawing on research from Billings et al.
Also, the test panel aligns with the 2024 American Diabetes Association Standards of Care.
GoPath Diagnostics CEO and medical director Jim Lu said: “DiabetesNow brings together the most relevant genetic markers in a single panel, helping providers better distinguish between complex diabetes presentations and offer more tailored care.”
